
Shares of Oklo (OKLO) jumped more than 6% on Wednesday after the U.S. Department of Energy (DOE) cleared its Groves-1 nuclear test reactor for unrestricted operations, a key step in the company’s plans to develop medical isotopes for cancer treatments.
The DOE cleared the final operational restriction on Groves-1, allowing the reactor to enter its research, testing and training phase.
The Texas-based facility will help Oklo test reactor equipment, improve operating procedures and train personnel for future projects, including its Aurora fast-fission nuclear power plants. The reactors are designed to supply electricity to AI data centers and industrial facilities.
In August, Groves-1 became the first reactor under the DOE's Reactor Pilot Program to achieve criticality on private land, generating a controlled, self-sustaining nuclear chain reaction less than a year after construction began.
Experience gained from operating Groves-1 will support Oklo’s planned Groves-2 Forge facility, the company said. Unlike Groves-1, which focuses on testing and training, Groves-2 will be used for medical isotope production, processing, packaging and transportation.
The facility will initially focus on lutetium-177, a radioactive isotope used in targeted cancer treatments that deliver radiation directly to cancer cells.
Retail sentiment surrounding OKLO remained ‘bullish’ over the past 24 hours, amid ‘high’ message volumes.
One user expects the stock to climb to at least $50 by the end of the year. This represents about 85% upside from current levels.
View this Stocktwits post
OKLO shares have been under heavy selling pressure this year, slumping more than 67%.
Also read: Lithium Americas Raises Flagship Project Cost Estimate By $900M – CEO Says Phase 1 Completion Targeted For Late 2027
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
Stay updated with all the latest Business NewsShare Market NewsIPOsGold PriceDA Hike8th Pay CommissionAsianet News Official App